• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    2/6/24 4:31:18 PM ET
    $ARWR
    $BFRI
    $DMK
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARWR alert in real time by email

    Gainers

    • Sharps Technology (NASDAQ:STSS) stock increased by 27.9% to $0.37 during Tuesday's after-market session. The company's market cap stands at $5.6 million.
    • DMK Pharmaceuticals (NASDAQ:DMK) stock moved upwards by 22.84% to $0.28. The company's market cap stands at $2.8 million.
    • Mira Pharmaceuticals (NASDAQ:MIRA) stock rose 11.6% to $1.25. The company's market cap stands at $18.4 million.
    • Vicarious Surgical (NYSE:RBOT) shares increased by 5.4% to $0.43. The company's market cap stands at $74.7 million.
    • Novo Integrated Sciences (NASDAQ:NVOS) stock increased by 4.97% to $0.77. The company's market cap stands at $13.7 million.
    • Galecto (NASDAQ:GLTO) stock moved upwards by 4.82% to $0.63. The company's market cap stands at $17.0 million.

    Losers

    • Exicure (NASDAQ:XCUR) stock declined by 10.4% to $0.64 during Tuesday's after-market session. The company's market cap stands at $5.5 million.
    • Yield10 Bioscience (NASDAQ:YTEN) shares fell 6.82% to $0.36. The company's market cap stands at $4.2 million.
    • Arrowhead Pharma (NASDAQ:ARWR) shares declined by 6.46% to $31.1. The company's market cap stands at $3.8 billion. As per the news, the Q1 earnings report came out today.
    • Biofrontera (NASDAQ:BFRI) stock declined by 5.94% to $0.84. The company's market cap stands at $1.4 million.
    • Varex Imaging (NASDAQ:VREX) shares decreased by 5.61% to $18.35. The company's market cap stands at $743.7 million. As per the news, the Q1 earnings report came out today.
    • Helius Medical Tech (NASDAQ:HSDT) stock fell 5.43% to $6.1. The company's market cap stands at $4.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ARWR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARWR
    $BFRI
    $DMK
    $GLTO

    CompanyDatePrice TargetRatingAnalyst
    Galecto Inc.
    $GLTO
    2/17/2026$45.00Buy
    UBS
    Galecto Inc.
    $GLTO
    1/7/2026$46.00Outperform
    Leerink Partners
    Galecto Inc.
    $GLTO
    12/1/2025$32.00Buy
    Guggenheim
    Varex Imaging Corporation
    $VREX
    8/23/2024$21.00Buy
    B. Riley Securities
    Arrowhead Pharmaceuticals Inc.
    $ARWR
    6/5/2024$31.00Neutral
    Goldman
    Yield10 Bioscience Inc.
    $YTEN
    2/8/2024Buy → Hold
    Lake Street
    Arrowhead Pharmaceuticals Inc.
    $ARWR
    12/4/2023$29.00Buy
    BofA Securities
    Arrowhead Pharmaceuticals Inc.
    $ARWR
    9/19/2023$33.00Neutral
    Citigroup
    More analyst ratings

    $ARWR
    $BFRI
    $DMK
    $GLTO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vicarious Surgical Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia Repair

    WALTHAM, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB:RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the "Company"), today announced the successful completion of initial integrated benchtop testing for its full suite of surgical instruments, required for its anticipated first clinical indication of ventral hernia repair, marking an important step toward design validation, clinical readiness, and the Company's targeted design freeze milestone. This milestone represents the first system-level performance evaluation of the Company's three core instruments: needle drivers, fenestrated graspers, and monopolar sc

    3/30/26 4:15:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Solana Company Reports Fourth Quarter and Full Year 2025 Financial Results

    NEWTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury ("DAT") dedicated to acquiring and holding Solana tokens ("SOL"), today announced results for the quarter and full year ended December 31, 2025. Fourth Quarter and Full Year Recent Business Updates Generated $5.1 million in staking rewards in the fourth quarter of 2025 and $5.5 million for the full year, as substantially all SOL holdings were staked throughout the periodRaised $29.9 million in 2025 through the Company's ATM programs, with proceeds used primarily to purchase SOL on an net asse

    3/30/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo

    – Patients with severe hypertriglyceridemia (sHTG) achieved an 83% median reduction in triglycerides (TG), with 96% of patients achieving TG levels below 500 mg/dL, a threshold associated with increased risk of acute pancreatitis – No adjudicated acute pancreatitis events occurred in any patient receiving plozasiran during the 2-year Phase 2b Open-Label Expansion (OLE) Study – Favorable and durable improvements in atherogenic lipoproteins, including remnant cholesterol, non-HDL cholesterol, and ApoB, were observed, with a safety profile consistent with earlier trials Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced long-term efficacy and safety data from a two-year long o

    3/28/26 10:30:00 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARWR
    $BFRI
    $DMK
    $GLTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Perkins Sherrie L

    4 - Solana Co (0001610853) (Issuer)

    4/2/26 5:00:33 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Straw Edward M

    4 - Solana Co (0001610853) (Issuer)

    4/2/26 5:00:20 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Buckman Paul

    4 - Solana Co (0001610853) (Issuer)

    4/2/26 5:00:22 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ARWR
    $BFRI
    $DMK
    $GLTO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ruemler Timothy James increased direct ownership by 294% to 40,218 units (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:45:47 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Crescenzo Andrew R. bought $256,400 worth of Option (40,000 units at $6.41) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:24:34 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Director Monroe Jason L. bought $512,800 worth of Option (80,000 units at $6.41) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:24:36 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $ARWR
    $BFRI
    $DMK
    $GLTO
    SEC Filings

    View All

    $ARWR
    $BFRI
    $DMK
    $GLTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Exicure Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - EXICURE, INC. (0001698530) (Filer)

    4/2/26 4:15:02 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Sharps Technology Inc.

    10-K - Sharps Technology Inc. (0001737995) (Filer)

    3/31/26 4:46:44 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by MIRA Pharmaceuticals Inc.

    10-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)

    3/31/26 2:02:37 PM ET
    $MIRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS initiated coverage on Galecto with a new price target

    UBS initiated coverage of Galecto with a rating of Buy and set a new price target of $45.00

    2/17/26 8:59:23 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Galecto with a new price target

    Leerink Partners initiated coverage of Galecto with a rating of Outperform and set a new price target of $46.00

    1/7/26 8:34:02 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Galecto with a new price target

    Guggenheim initiated coverage of Galecto with a rating of Buy and set a new price target of $32.00

    12/1/25 8:28:46 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARWR
    $BFRI
    $DMK
    $GLTO
    Leadership Updates

    Live Leadership Updates

    View All

    Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

    NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:  S&P MidCap 400 constituent Ciena Corp. (NYSE:CIEN) will replace Dayforce Inc. (NYSE:DAY) in the S&P 500, S&P SmallCap 600 constituent Arrowhead Pharmaceuticals Inc. (NASD: ARWR) will replace Ciena in the S&P MidCap 400, and ADT Inc. (NYSE:ADT) will replace Arrowhead Pharmaceuticals in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 9. Thoma Bravo L.P. acquired Dayforce in a deal that closed today.OneSpaWorld Holdings Ltd. (NASD: OSW) will replace Dynavax Technologies Corp. (NASD: DVAX) in the S&P SmallCap 600 effec

    2/4/26 6:15:00 PM ET
    $ADT
    $ARWR
    $CIEN
    Diversified Commercial Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones

    DMR-001, a potentially best-in-class mutant calreticulin ("mutCALR") targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human dosing via subcutaneous administrationRecent addition of deep hematology/oncology drug development experience with the appointment of a Chief Operating Officer and Chief Medical OfficerPipeline of additional candidates advancing to the clinic, with first IND submission of DMR-002 expected in second half of 2026Cash balance, following $285M raised in the November PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinical proof-of-concept data for DMR-001 an

    1/12/26 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Announces Key Additions to Leadership Team

    Deep hematology/oncology drug development experience added with the appointment of Sherwin Sattarzadeh as Chief Operating Officer and Becker Hewes as Chief Medical Officer DMR-001, a potentially best-in-class mutant calreticulin ("mutCALR") targeting monoclonal antibody, on track for IND submission in mid-2026 with anticipated first-in-human dosing via subcutaneous administration Cash balance, including $285 million raised in November 2025 PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinical proof-of-concept data for DMR-001 anticipated in 2027 BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. ("Galecto" or the "Company"), a biotech

    1/6/26 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARWR
    $BFRI
    $DMK
    $GLTO
    Financials

    Live finance-specific insights

    View All

    Solana Company Reports Fourth Quarter and Full Year 2025 Financial Results

    NEWTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury ("DAT") dedicated to acquiring and holding Solana tokens ("SOL"), today announced results for the quarter and full year ended December 31, 2025. Fourth Quarter and Full Year Recent Business Updates Generated $5.1 million in staking rewards in the fourth quarter of 2025 and $5.5 million for the full year, as substantially all SOL holdings were staked throughout the periodRaised $29.9 million in 2025 through the Company's ATM programs, with proceeds used primarily to purchase SOL on an net asse

    3/30/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Exicure, Inc. Reports Full Year 2025 Financial Results

    REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position: Cash and cash equivalents were $3.7 million as of December 31, 2025, compared to $12.5 million as of December 31, 2024. Our current liquidity may not be sufficient to fund operations for the next 12 months. Additional financing will be required to support ongoing operations, continue the exploration of strategic alternatives, and pursue any alternatives that we identify. Research and Development (R&D) Expense: Research and development expenses were $3.3 million for the ye

    3/25/26 4:18:31 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Solana Company to Release Fourth Quarter and Full Year 2025 Operating Results on March 30, 2026

    NEWTOWN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to acquiring and holding Solana (SOL), today announced that the Company will release its fourth quarter and full year operating results on Monday, March 30, 2026, after market close. Management will host a conference call to discuss the results and provide an expanded business update as follows: Date:Monday, March 30, 2026Time:4:30 p.m. Eastern TimeWebcast:Click hereParticipant call link:Click here (register to receive unique PIN and dial-in number)   The webcast will be archived unde

    3/24/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ARWR
    $BFRI
    $DMK
    $GLTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biofrontera Inc.

    SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

    11/14/24 3:54:03 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biofrontera Inc.

    SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

    11/14/24 1:13:39 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care